Condition

High-risk Prostate Cancer clinical trials and research

• 15Clinical trials
• 11NIH research projects
• 5Countries

Newest High-risk Prostate Cancer clinical trials

All recruiting trials (15)

• Radiation therapy options for high-risk prostate cancer

  This trial tests different ways of giving radiation therapy to see which balance best controls the cancer with the fewest side effects in men with high-risk, non-metastatic prostate cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07751159

• Repeated PSMA PET scans to monitor treatment response in clinically significant prostate cancer.

  This project will test whether doing a PSMA PET/CT before treatment and again after treatment (or at early PSA rise) helps track response in people with newly diagnosed clinically significant (Gleason ≥7) prostate cancer.

  Recruiting at 9 sites Xijing Hospital · Lanzhou, Gansu and 8 other locations · NCT07553780

• Androgen-guided PSMA-PET-boost for prostate cancer treated with ADT and SBRT

  This study tests whether using PSMA-PET imaging during hormone therapy can help doctors target remaining cancer with a focused SBRT boost in men with intermediate- or high-risk prostate cancer.

  Recruiting at 2 sites Phase 2 Brigham and Women's Hospital · Boston, Massachusetts and 3 other locations · NCT07393867

• Delayed pelvic [68Ga]-PSMA PET/CT using the first CT for men with high-risk prostate cancer

  This test tries to see if doing a delayed pelvic [68Ga]-PSMA PET that reuses the initial CT (so no second CT) keeps image quality while lowering radiation for men with high‑risk or recurrent prostate cancer.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Italy · NCT07357259

• Tb-PSMA radionuclide treatment before radical prostatectomy for locally advanced prostate cancer

  This will try giving a Tb-PSMA radionuclide treatment to men with high-risk, locally advanced prostate cancer before prostate removal to see if it is safe and reduces tumor burden.

  Recruiting Phase 1/2 Rabin Medical Center · Petah Tikva · NCT07208240

• Adaptive stereotactic body radiotherapy with pelvic treatment and focal dose boost for high-risk prostate cancer

  This trial will try an adaptive form of focused high-dose radiation to the prostate and pelvic lymph nodes, with an extra dose to the main tumor area, for men with high-risk prostate cancer to see if it improves outcomes and cost-effectiveness compared with standard radiotherapy.

  Recruiting Center Eugene Marquis · Rennes · NCT07189598

• Comparing Lutetium-177 and Actinium-225 PSMA-targeted radiation before prostatectomy

  This will test whether giving one of two PSMA-targeted radiation drugs (Lutetium-177 or Actinium-225) before prostate removal works differently in men with high or very high-risk localized prostate cancer.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07054346

• Hormone therapy with darolutamide and pembrolizumab before prostate removal, then pembrolizumab after surgery for high-risk prostate cancer

  This trial will test whether giving androgen-deprivation therapy plus darolutamide and pembrolizumab before prostate removal, followed by pembrolizumab after surgery, helps men with genomically defined high-risk localized prostate cancer.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07027124

• Observational study on radiation therapy and hormone treatment for high-risk prostate cancer

  This study is testing whether combining a special type of radiation therapy with hormone treatment can help men with high-risk prostate cancer do better and have fewer side effects compared to regular radiation.

  Recruiting Istituto Clinico Humanitas · Bergamo, Bergamo and 2 other locations · NCT06949254

• Epigenetic therapy given before prostatectomy for men with prostate cancer

  This will try short courses of epigenetic drugs before prostatectomy to see if they make tumors more sensitive to the immune system in men with high-risk localized prostate cancer.

  Recruiting Early Phase 1 Cedars-Sinai Medical Center · Los Angeles, California · NCT06888102

• Surgical treatment for high-risk prostate cancer with or without apalutamide

  This study is testing if adding a medication called apalutamide to standard hormone therapy after surgery can help men with high-risk prostate cancer live better and longer.

  Recruiting Phase 2 A.O.U. Città della Salute e della Scienza · Torino, To · NCT06758882

• FK-PC101 vaccine for men with high-risk prostate cancer after surgery

  This study is testing a new vaccine for men with high-risk prostate cancer after surgery to see if it can help prevent the cancer from coming back.

  Recruiting at 2 sites Phase 2 Cellvax Therapeutics Inc · Chicago, Illinois and 2 other locations · NCT06636682

• Neoadjuvant treatment for high-risk localized prostate cancer

  This study is testing a new combination treatment for men with high-risk localized prostate cancer to see if it can shrink tumors before surgery and improve their chances of a successful outcome.

  Recruiting at 8 sites Phase 2 VA Office of Research and Development · West Los Angeles, California and 8 other locations · NCT05593497

• Intense hormone therapy before surgery for advanced prostate cancer

  This study is testing whether a stronger hormone treatment before surgery can help men with advanced prostate cancer do better than the usual hormone therapy.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT05406999

• Gene therapy plus hormone therapy, radiotherapy, and surgery for high-risk prostate cancer

  This phase II trial tests HSV-tk gene therapy with valacyclovir alongside hormone therapy, brachytherapy, external beam radiotherapy, and prostatectomy in men with untreated high-risk prostate cancer.

  Recruiting Phase 2 The Methodist Hospital Research Institute · Houston, Texas · NCT03541928

NIH-funded research (11)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Overcoming Resistance to AR-Targeted Therapy in High-Risk Prostate Cancer

  Researchers are studying why some high-risk prostate cancers stop responding to AR pathway inhibitors and trying new strategies to improve outcomes for men with aggressive, localized disease.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11411374

• Tumor environment players in advanced prostate cancer spread

  Researchers are studying how the tissue around prostate tumors helps cancer spread, in men with high-risk disease.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11398977

• Integrated genomic and AI pathology biomarkers to guide high-risk prostate cancer treatment

  A prostate cancer research project tests how genomic and AI-based pathology tools can help tailor who should receive added ARSI therapy with standard radiotherapy and hormone treatment.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11395376

• Mitochondrial changes in high-risk prostate cancer

  This project looks at changes in mitochondrial DNA and cell energy systems in men, especially African American men, with high‑risk prostate cancer to find markers that predict who will develop aggressive disease.

  NIH research Rutgers Biomedical and Health Sciences · Newark, UNITED STATES · NIH-11302709

• Understanding mitochondrial changes in high-risk prostate cancer

  This study is looking at how changes in mitochondrial DNA might affect prostate cancer in African American men, who are more likely to face serious cases, with the hope of finding ways to predict and improve treatment for those at risk.

  NIH research Rutgers Biomedical and Health Sciences · Newark, UNITED STATES · NIH-11231990

• How high-risk prostate tumors and nearby cells kick off cancer spread

  This project looks at how high-risk prostate tumors and the immune and support cells around them start to spread by using advanced scans and detailed analysis of removed prostate tissue.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11184186

• Blocking stromal signals to make androgen-blocking treatment work better for high-risk prostate cancer

  Researchers are trying to improve outcomes for people with high-risk localized prostate cancer by blocking signals from nearby stromal cells so androgen-blocking drugs work more fully.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11173726

• Investigating how the tumor environment influences the spread of high-risk prostate cancer

  This study is looking at how the area around prostate tumors affects the spread of high-risk prostate cancer, using advanced imaging to help find better treatment options for patients like you.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-10899411

• Finding better ways to personalize treatment for high-risk prostate cancer

  This study is looking to help men with high-risk prostate cancer by finding special markers in their tumors that can guide doctors in choosing the best treatment for each person, so some can get stronger therapies like chemotherapy while others can skip extra side effects from long hormone treatments.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-10868607

• Using tiny silica particles to improve surgery for high-risk prostate cancer

  This study is looking to help patients with high-risk prostate cancer by using special tiny particles that light up cancerous tissues during surgery, making it easier for doctors to see and remove all the cancer while reducing the chances of it coming back.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-10784691

• Targeted radiation therapy for high-risk prostate cancer

  This study is exploring a new way to treat high-risk prostate cancer by using special imaging techniques to find cancer spots more accurately, so patients can receive targeted radiation therapy in just five sessions, which aims to reduce side effects and improve treatment results.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-10440533

Related topics

Quick answers

How many High-risk Prostate Cancer clinical trials are recruiting right now?

15, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in United States (8 trials), Italy (3 trials), China (2 trials), France (1 trial), Israel (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 8, Early Phase 1: 1, Phase 1/2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →